CoChat

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group

Open access
Ankerst, Donna P., Boeck, Andreas, Freedland, Stephen J., Thompson, Ian M., Cronin, Angel M., Roobol, Monique J., Hugosson, Jonas, Stephen Jones, J., Kattan, Michael W., Klein, Eric A., Hamdy, Freddie, Neal, David, Donovan, Jenny, Parekh, Dipen J., Klocker, Helmut, Horninger, Wolfgang, Benchikh, Amine, Salama, Gilles, Villers, Arnauld, Moreira, Daniel M., Schröder, Fritz H., Lilja, Hans, Vickers, Andrew J. · 2012 · World Journal of Urology
Cited by 65

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

ObjectivesTo evaluate the discrimination, calibration, and net benefit performance of the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) across five European randomized study of screening for prostate cancer (ERSPC), 1 United Kingdom, 1 Austrian, and 3 US biopsy cohorts.MethodsPCPTRC risks were calculated for 25,733 biopsies using prostate-specific antigen (PSA), digital rectal examination, family history, history of prior biopsy, and imputation for missing covariates. Predictions were evaluated using the areas underneath the receiver operating characteristic curves (AUC), discrimination slopes, chi-square tests of goodness of fit, and net benefit decision curves.ResultsAUCs of the PCPTRC ranged from a low of 56% in the ERSPC Goeteborg Rounds 2–6 cohort to a high of 72% in the ERSPC Goeteborg Round 1 cohort and were statistically significantly higher than that of PSA in 6 out of the 10 cohorts. The PCPTRC was well calibrated in the SABOR, Tyrol, and Durham cohorts. There was limited to no net benefit to using the PCPTRC for biopsy referral compared to biopsying all or no men in all five ERSPC cohorts and benefit within a limited range of risk thresholds in all other cohorts.ConclusionsExternal validation of the PCPTRC across ten cohorts revealed varying degree of success highly dependent on the cohort, most likely due to different criteria for and work-up before biopsy. Future validation studies of new calculators for prostate cancer should acknowledge the potential impact of the specific cohort studied when reporting successful versus failed validation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00345-011-0818-5

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 65

Metadata

Authors
Ankerst, D. P., Boeck, A., Freedland, S. J., Thompson, I. M., Cronin, A. M., Roobol, M. J., Hugosson, J., Stephen Jones, J., Kattan, M. W., Klein, E. A., Hamdy, F., Neal, D., Donovan, J., Parekh, D. J., Klocker, H., Horninger, W., Benchikh, A., Salama, G., Villers, A., Moreira, D. M., Schröder, F. H., Lilja, H., & Vickers, A. J.
Venue
World Journal of Urology
Published
2011-12-31
Volume
30
Issue
2
Pages
181-187
ISSN
  • 0724-4983 (ISSN-L)
  • 1433-8726
OpenAlex
W1990838727
Cited by
65
References
5
FWCI
4.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. https://app.cochat.ai/papers/10.1007/s00345-011-0818-5
The paper
Ankerst, D. P., Boeck, A., Freedland, S. J., Thompson, I. M., Cronin, A. M., Roobol, M. J., Hugosson, J., Stephen Jones, J., Kattan, M. W., Klein, E. A., Hamdy, F., Neal, D., Donovan, J., Parekh, D. J., Klocker, H., Horninger, W., Benchikh, A., Salama, G., Villers, A., . . . Vickers, A. J. (2012). Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World Journal of Urology. https://doi.org/10.1007/s00345-011-0818-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.